@chilunsin CAP-1002 is a cell therapy. It is an allogeneic...

@chilunsin

CAP-1002 is a cell therapy. It is an allogeneic product, meaning it is manufactured from donor heart tissue and then stored until needed for use. CAP-1002 consists of allogeneic cardiosphere-derived cells, a unique population of cells that contains cardiac progenitor cells. It is thought to decrease inflammation and muscle degeneration while exerting positive effects on muscle regeneration, all of which may translate into patients retaining muscle function for a longer period of time

Not like us directly targeting Inflamation but who knows what trial outcomes are going to be

We dont hence the trial

We were not targeting increase in muscle mass but it looks like we could be onto it




Taken from the ppmd site

They are looking at improving multiple aspects of the disease

https://www.parentprojectmd.org/drug-development-pipeline/cap-1002/

When i said, side by side i was talking clinical advancement under regulatory guidance